+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Joint Pain Injections Market - Global Forecast 2026-2032- Product Image
Joint Pain Injections Market - Global Forecast 2026-2032- Product Image
Sale

Joint Pain Injections Market - Global Forecast 2026-2032

  • Report

  • 194 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4905012
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Joint Pain Injections Market is projected to reach USD 5.15 Billion in 2026. It is expected to continue growing at a CAGR of 10.19%, reaching USD 9.28 Billion by 2032.

Joint pain injections are a critical non-surgical intervention for osteoarthritis, inflammatory arthritis, sports injuries, and degenerative musculoskeletal disease. Demand is supported by aging populations, higher obesity prevalence, longer active lifestyles, and the clinical need to delay or avoid joint replacement when appropriate.

The landscape spans corticosteroids, hyaluronic acid, platelet-rich plasma, local anesthetics, and emerging regenerative or biologic approaches. WHO reports that osteoarthritis affects more than 500 million people globally, and CDC data show that doctor-diagnosed arthritis affects over 50 million U.S. adults, reinforcing sustained need for evidence-based joint pain relief, intra-articular injections, and outpatient musculoskeletal care.

Transformative Shifts in the Joint Pain Injection Landscape

The joint pain injection landscape is shifting from episodic pain treatment toward precision-guided, outcomes-driven musculoskeletal care. Ultrasound-guided injections, ambulatory orthopedic centers, and integrated pain management pathways are improving procedural accuracy, documentation, patient experience, and clinic throughput.

At the same time, payers and regulators are demanding stronger clinical evidence, especially for higher-cost products and regenerative therapies. Providers are increasingly differentiating through image guidance, standardized injection protocols, real-world outcomes tracking, and patient education around expected duration of relief, safety considerations, and repeat-use limits.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to influence the full joint pain injection pathway, from diagnosis and patient selection to workflow automation and outcomes monitoring. AI-enabled imaging tools can help quantify joint space narrowing, effusion, synovitis, cartilage loss, and structural progression, supporting more consistent treatment decisions in osteoarthritis and other joint disorders.

The cumulative impact is strongest when AI is paired with electronic health records, claims data, imaging archives, and patient-reported outcomes. These systems can help identify likely responders, flag safety risks, optimize scheduling, reduce administrative burden, and generate real-world evidence needed by regulators, payers, and clinical leaders evaluating joint pain injection therapies.

Key Regional Insights

Asia-Pacific is expanding as China, India, Japan, South Korea, and Australia face aging populations, rising osteoarthritis burden, and broader access to orthopedic, rheumatology, rehabilitation, and pain clinics. Japan’s super-aged population, China’s scale of chronic disease management, India’s expanding private specialty care, and Australia and South Korea’s strong imaging infrastructure support increased use of image-guided joint injections and evidence-based musculoskeletal procedures.

North America remains highly developed due to established ambulatory care networks, advanced imaging adoption, widespread sports medicine services, and high patient awareness of corticosteroid injections, hyaluronic acid injections, and platelet-rich plasma procedures. Latin America is led by Brazil and Mexico, where private healthcare growth, urban specialty clinics, and rising access to orthopedic care support premium injection therapies. Europe is shaped by evidence-based guidelines, health technology assessment, reimbursement discipline, and cost-containment policies, particularly across major public health systems. The Middle East, especially Gulf markets, favors advanced outpatient care, specialist-led musculoskeletal services, and hospital modernization, while Africa remains more access-constrained, with development tied to urban private clinics, essential pain management availability, workforce capacity, and affordability.

Key Economic and Strategic Group Insights

ASEAN markets are gaining momentum as medical tourism, expanding private hospitals, urban specialty centers, and rising middle-class demand improve access to orthopedic injections and image-guided pain procedures. GCC countries prioritize premium musculoskeletal services, specialist-led care, hospital modernization, and outpatient treatment capacity, supporting adoption of advanced injection workflows and imaging-enabled procedures.

The European Union emphasizes regulatory compliance, clinical evidence, pharmacovigilance, medical device oversight, and reimbursement discipline under evolving healthcare frameworks. BRICS countries provide scale through large patient populations, expanding specialty care, chronic disease burden, and local manufacturing potential. G7 markets lead in clinical guidelines, reimbursement governance, digital health infrastructure, real-world evidence generation, and innovation funding, while NATO countries increasingly value resilient medical supply chains, care continuity, and standardized clinical readiness across essential and specialty therapies.

Key Country Insights

The United States is highly procedure-intensive, supported by ambulatory care networks, sports medicine clinics, orthopedic practices, rheumatology services, and interventional pain management providers. Canada emphasizes guideline-based access and publicly funded care pathways, while Mexico and Brazil benefit from private-sector expansion, medical tourism in select urban centers, and growing specialist availability. The United Kingdom, Germany, France, Italy, and Spain are shaped by public reimbursement, clinical evidence thresholds, aging demographics, and guideline-driven adoption of intra-articular injection therapies.

Russia maintains demand through large orthopedic, rheumatology, and rehabilitation needs across a broad population base. China and India offer high-volume growth potential as specialty care expands, chronic musculoskeletal disease awareness rises, and urban hospitals adopt more advanced procedural capabilities. Japan has strong clinical need due to population aging and high osteoarthritis prevalence, while Australia and South Korea combine advanced imaging access, sports medicine expertise, digital health maturity, and high patient awareness to support evidence-based use of joint pain injections.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence generation, especially comparative effectiveness data, durability of pain relief, functional improvement, safety across repeat-use cycles, and patient-reported outcomes. Partnerships with orthopedic groups, rheumatology networks, ambulatory surgery centers, rehabilitation providers, and imaging specialists can improve adoption, protocol consistency, and procedural standardization.

Organizations should also invest in AI-ready data platforms, physician training, ultrasound-guided injection programs, real-world evidence systems, and payer-facing health economic models. Clear patient segmentation, compliant clinical claims, responsible positioning of regenerative therapies, supply resilience, and region-specific reimbursement strategies will be essential for sustainable growth in joint pain injection therapies.

Research Methodology

The research approach integrates secondary data from public health agencies, regulatory bodies, clinical guidelines, peer-reviewed literature, reimbursement policies, and public disclosures. Sources such as WHO, CDC, OECD, national health ministries, clinical society guidance, and regulator databases are used to validate disease burden, demographic drivers, treatment standards, and market access conditions.

Findings are triangulated through therapy segmentation, regional demand indicators, technology adoption patterns, regulatory pathways, reimbursement dynamics, and stakeholder analysis across manufacturers, providers, payers, distributors, and care-delivery networks. Emphasis is placed on verified evidence, real-world utilization signals, clinical relevance, and defensible interpretation of market drivers without relying on unsupported estimates or forecasts.

Conclusion

Joint pain injections remain an important bridge between conservative therapy and surgery, particularly for patients seeking functional improvement and temporary pain relief. Demand is reinforced by osteoarthritis prevalence, aging populations, sports injuries, obesity-related joint stress, and pressure to manage care in lower-cost outpatient settings.

Future competitiveness will depend on clinical evidence, image-guided precision, payer acceptance, AI-enabled patient stratification, responsible positioning of regenerative therapies, and consistent safety monitoring. Organizations that combine data, training, compliance, access strategy, and real-world outcomes capabilities will be best placed to lead in the evolving joint pain injections landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Joint Pain Injections Market, by Molecule Type
7.1. Introduction
7.2. Corticosteroids
7.2.1. Betamethasone
7.2.2. Methylprednisolone Acetate
7.2.3. Triamcinolone Acetonide
7.3. Hyaluronic Acid
7.3.1. Cross-Linked
7.3.2. Linear
7.4. Platelet-Rich Plasma
8. Joint Pain Injections Market, by Route Of Administration
8.1. Introduction
8.2. Intra-Articular
8.3. Intramuscular
8.3.1. Deep Tissue
8.3.2. Superficial
8.4. Peri-Articular
8.4.1. Landmark-Based
8.4.2. Ultrasound-Guided
9. Joint Pain Injections Market, by Indication
9.1. Introduction
9.2. Osteoarthritis
9.3. Rheumatoid Arthritis
9.4. Gout
9.5. Bursitis
9.6. Tendinitis
9.7. Synovitis
10. Joint Pain Injections Market, by Patient Age Group
10.1. Introduction
10.2. Under 18 Years
10.3. 18 To 64 Years
10.4. 65 Years & Older
11. Joint Pain Injections Market, by Joint Type
11.1. Introduction
11.2. Knee
11.3. Hip
11.4. Shoulder
11.5. Ankle
11.6. Elbow
12. Joint Pain Injections Market, by End User
12.1. Introduction
12.2. Ambulatory Surgical Centers
12.3. Hospitals
12.4. Orthopedic Clinics
12.5. Rheumatology Clinics
13. Joint Pain Injections Market, by Region
13.1. Asia-Pacific
13.2. Europe
13.3. North America
13.4. Latin America
13.5. Africa
13.6. Middle East
14. Joint Pain Injections Market, by Group
14.1. NATO
14.2. G7
14.3. European Union
14.4. BRICS
14.5. ASEAN
14.6. GCC
15. Joint Pain Injections Market, by Country
15.1. United States
15.2. China
15.3. Germany
15.4. Japan
15.5. India
15.6. United Kingdom
15.7. France
15.8. Canada
15.9. Italy
15.10. Australia
15.11. South Korea
15.12. Brazil
15.13. Mexico
15.14. Russia
15.15. Spain
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Allergan plc
17.2. Anika Therapeutics, Inc.
17.3. Anterogen Co., Ltd.
17.4. Bioiberica S.A.U.
17.5. Bioventus LLC
17.6. Boehringer Ingelheim GmbH
17.7. Chugai Pharmaceutical Co., Ltd.
17.8. Contipro a.s.
17.9. Eli Lilly and Company
17.10. Ferring B.V.
17.11. Fidia Farmaceutici S.p.A.
17.12. Hangzhou Singclean Medical Products Co., Ltd.
17.13. LG Chem Ltd.
17.14. Mylan N.V.
17.15. Novartis AG
17.16. Pacira Pharmaceuticals, Inc
17.17. Pfizer Inc.
17.18. Sanofi S.A
17.19. Seikagaku Corporation
17.20. Shanghai Jingfeng Pharmaceutical Co., Ltd.
17.21. Smith & Nephew plc
17.22. Teva Pharmaceutical Industries Ltd.
17.23. Yantai Dongcheng Pharmaceutical Group Co., Ltd.
17.24. Zimmer Biomet Holdings, Inc.
List of Figures
FIGURE 1. GLOBAL JOINT PAIN INJECTIONS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL JOINT PAIN INJECTIONS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL JOINT PAIN INJECTIONS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL JOINT PAIN INJECTIONS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 9. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2032 (%)
FIGURE 13. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 17. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL JOINT PAIN INJECTIONS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL JOINT PAIN INJECTIONS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL JOINT PAIN INJECTIONS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL BETAMETHASONE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL BETAMETHASONE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL BETAMETHASONE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL METHYLPREDNISOLONE ACETATE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL METHYLPREDNISOLONE ACETATE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL METHYLPREDNISOLONE ACETATE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL TRIAMCINOLONE ACETONIDE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL TRIAMCINOLONE ACETONIDE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL TRIAMCINOLONE ACETONIDE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL HYALURONIC ACID MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL HYALURONIC ACID MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL HYALURONIC ACID MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL CROSS-LINKED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL CROSS-LINKED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL CROSS-LINKED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL LINEAR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL LINEAR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL LINEAR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL PLATELET-RICH PLASMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL PLATELET-RICH PLASMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL PLATELET-RICH PLASMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL INTRA-ARTICULAR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL INTRA-ARTICULAR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL INTRA-ARTICULAR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL DEEP TISSUE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL DEEP TISSUE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL DEEP TISSUE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL SUPERFICIAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL SUPERFICIAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL SUPERFICIAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL PERI-ARTICULAR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL PERI-ARTICULAR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL PERI-ARTICULAR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL LANDMARK-BASED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL LANDMARK-BASED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL LANDMARK-BASED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL ULTRASOUND-GUIDED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL ULTRASOUND-GUIDED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL ULTRASOUND-GUIDED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL OSTEOARTHRITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL OSTEOARTHRITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL OSTEOARTHRITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL GOUT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL GOUT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL GOUT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL BURSITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL BURSITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL BURSITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL TENDINITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL TENDINITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL TENDINITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL SYNOVITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL SYNOVITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL SYNOVITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL UNDER 18 YEARS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL UNDER 18 YEARS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL UNDER 18 YEARS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL 18 TO 64 YEARS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL 18 TO 64 YEARS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL 18 TO 64 YEARS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL 65 YEARS & OLDER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL 65 YEARS & OLDER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL 65 YEARS & OLDER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL KNEE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL KNEE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL KNEE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL HIP MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL HIP MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL HIP MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL SHOULDER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL SHOULDER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL SHOULDER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL ANKLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL ANKLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL ANKLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL ELBOW MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL ELBOW MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL ELBOW MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL ORTHOPEDIC CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL ORTHOPEDIC CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL ORTHOPEDIC CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL RHEUMATOLOGY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL RHEUMATOLOGY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL RHEUMATOLOGY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 109. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 110. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 111. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 112. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2017-2032 (USD MILLION)
TABLE 113. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 114. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2017-2032 (USD MILLION)
TABLE 115. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2017-2032 (USD MILLION)
TABLE 116. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 117. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 118. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2017-2032 (USD MILLION)
TABLE 119. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 120. EUROPE JOINT PAIN INJECTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 121. EUROPE JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 122. EUROPE JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 123. EUROPE JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2017-2032 (USD MILLION)
TABLE 124. EUROPE JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 125. EUROPE JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2017-2032 (USD MILLION)
TABLE 126. EUROPE JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2017-2032 (USD MILLION)
TABLE 127. EUROPE JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 128. EUROPE JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 129. EUROPE JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2017-2032 (USD MILLION)
TABLE 130. EUROPE JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 131. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 132. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 133. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 134. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2017-2032 (USD MILLION)
TABLE 135. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 136. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2017-2032 (USD MILLION)
TABLE 137. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2017-2032 (USD MILLION)
TABLE 138. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 139. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 140. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2017-2032 (USD MILLION)
TABLE 141. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 142. LATIN AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 143. LATIN AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 144. LATIN AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 145. LATIN AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2017-2032 (USD MILLION)
TABLE 146. LATIN AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 147. LATIN AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2017-2032 (USD MILLION)
TABLE 148. LATIN AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2017-2032 (USD MILLION)
TABLE 149. LATIN AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 150. LATIN AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 151. LATIN AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2017-2032 (USD MILLION)
TABLE 152. LATIN AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 153. AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 154. AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 155. AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 156. AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2017-2032 (USD MILLION)
TABLE 157. AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 158. AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2017-2032 (USD MILLION)
TABLE 159. AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2017-2032 (USD MILLION)
TABLE 160. AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 161. AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 162. AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2017-2032 (USD MILLION)
TABLE 163. AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 164. MIDDLE EAST JOINT PAIN INJECTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 165. MIDDLE EAST JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 166. MIDDLE EAST JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 167. MIDDLE EAST JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2017-2032 (USD MILLION)
TABLE 168. MIDDLE EAST JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 169. MIDDLE EAST JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2017-2032 (USD MILLION)
TABLE 170. MIDDLE EAST JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2017-2032 (USD MILLION)
TABLE 171. MIDDLE EAST JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 172. MIDDLE EAST JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 173. MIDDLE EAST JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2017-2032 (USD MILLION)
TABLE 174. MIDDLE EAST JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 175. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 176. NATO JOINT PAIN INJECTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 177. NATO JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 178. NATO JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 179. NATO JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2017-2032 (USD MILLION)
TABLE 180. NATO JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 181. NATO JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2017-2032 (USD MILLION)
TABLE 182. NATO JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2017-2032 (USD MILLION)
TABLE 183. NATO JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 184. NATO JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 185. NATO JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2017-2032 (USD MILLION)
TABLE 186. NATO JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 187. G7 JOINT PAIN INJECTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 188. G7 JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 189. G7 JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 190. G7 JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2017-2032 (USD MILLION)
TABLE 191. G7 JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 192. G7 JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2017-2032 (USD MILLION)
TABLE 193. G7 JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2017-2032 (USD MILLION)
TABLE 194. G7 JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 195. G7 JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 196. G7 JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2017-2032 (USD MILLION)
TABLE 197. G7 JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 198. EUROPEAN UNION JOINT PAIN INJECTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 199. EUROPEAN UNION JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 200. EUROPEAN UNION JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 201. EUROPEAN UNION JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2017-2032 (USD MILLION)
TABLE 202. EUROPEAN UNION JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 203. EUROPEAN UNION JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2017-2032 (USD MILLION)
TABLE 204. EUROPEAN UNION JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2017-2032 (USD MILLION)
TABLE 205. EUROPEAN UNION JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 206. EUROPEAN UNION JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 207. EUROPEAN UNION JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2017-2032 (USD MILLION)
TABLE 208. EUROPEAN UNION JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 209. BRICS JOINT PAIN INJECTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 210. BRICS JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 211. BRICS JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 212. BRICS JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2017-2032 (USD MILLION)
TABLE 213. BRICS JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 214. BRICS JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2017-2032 (USD MILLION)
TABLE 215. BRICS JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2017-2032 (USD MILLION)
TABLE 216. BRICS JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 217. BRICS JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 218. BRICS JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2017-2032 (USD MILLION)
TABLE 219. BRICS JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 220. ASEAN JOINT PAIN INJECTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 221. ASEAN JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 222. ASEAN JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 223. ASEAN JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2017-2032 (USD MILLION)
TABLE 224. ASEAN JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 225. ASEAN JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2017-2032 (USD MILLION)
TABLE 226. ASEAN JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2017-2032 (USD MILLION)
TABLE 227. ASEAN JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 228. ASEAN JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 229. ASEAN JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2017-2032 (USD MILLION)
TABLE 230. ASEAN JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 231. GCC JOINT PAIN INJECTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 232. GCC JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 233. GCC JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 234. GCC JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2017-2032 (USD MILLION)
TABLE 235. GCC JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 236. GCC JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2017-2032 (USD MILLION)
TABLE 237. GCC JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2017-2032 (USD MILLION)
TABLE 238. GCC JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 239. GCC JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 240. GCC JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2017-2032 (USD MILLION)
TABLE 241. GCC JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 242. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 243. UNITED STATES JOINT PAIN INJECTIONS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 244. UNITED STATES JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 245. UNITED STATES JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 246. UNITED STATES JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2017-2032 (USD MILLION)
TABLE 247. UNITED STATES JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 248. UNITED STATES JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2017-2032 (USD MILLION)
TABLE 249. UNITED STATES JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2017-2032 (USD MILLION)
TABLE 250. UNITED STATES JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 251. UNITED STATES JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 252. UNITED STATES JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2017-2032 (USD MILLION)
TABLE 253. UNITED STATES JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 254. CHINA JOINT PAIN INJECTIONS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 255. CHINA JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 256. CHINA JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 257. CHINA JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2017-2032 (USD MILLION)
TABLE 258. CHINA JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 259. CHINA JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2017-2032 (USD MILLION)
TABLE 260. CHINA JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2017-2032 (USD MILLION)
TABLE 261. CHINA JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 262. CHINA JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 263. CHINA JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2017-2032 (USD MILLION)
TABLE 264. CHINA JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 265. GERMANY JOINT PAIN INJECTIONS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 266. GERMANY JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 267. GERMANY JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 268. GERMANY JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2017-2032 (USD MILLION)
TABLE 269. GERMANY JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 270. GERMANY JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2017-2032 (USD MILLION)
TABLE 271. GERMANY JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2017-2032 (USD MILLION)
TABLE 272. GERMANY JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 273. GERMANY JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 274. GERMANY JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2017-2032 (USD MILLION)
TABLE 275. GERMANY JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 276. JAPAN JOINT PAIN INJECTIONS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 277. JAPAN JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 278. JAPAN JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 279. JAPAN JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2017-2032 (USD MILLION)
TABLE 280. JAPAN JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 281. JAPAN JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2017-2032 (USD MILLION)
TABLE 282. JAPAN JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2017-2032 (USD MILLION)
TABLE 283. JAPAN JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 284. JAPAN JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 285. JAPAN JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2017-2032 (USD MILLION)
TABLE 286. JAPAN JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 287. INDIA JOINT PAIN INJECTIONS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 288. INDIA JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 289. INDIA JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 290. INDIA JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2017-2032 (USD MILLION)
TABLE 291. INDIA JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 292. INDIA JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2017-2032 (USD MILLION)
TABLE 293. INDIA JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2017-2032 (USD MILLION)
TABLE 294. INDIA JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 295. INDIA JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 296. INDIA JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2017-2032 (USD MILLION)
TABLE 297. INDIA JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 298. UNITED KINGDOM JOINT PAIN INJECTIONS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 299. UNITED KINGDOM JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 300. UNITED KINGDOM JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 301. UNITED KINGDOM JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2017-2032 (USD MILLION)
TABLE 302. UNITED KINGDOM JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 303. UNITED KINGDOM JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2017-2032 (USD MILLION)
TABLE 304. UNITED KINGDOM JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2017-2032 (USD MILLION)
TABLE 305. UNITED KINGDOM JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 306. UNITED KINGDOM JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 307. UNITED KINGDOM JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2017-2032 (USD MILLION)
TABLE 308. UNITED KINGDOM JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 309. FRANCE JOINT PAIN INJECTIONS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 310. FRANCE JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 311. FRANCE JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 312. FRANCE JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2017-2032 (USD MILLION)
TABLE 313. FRANCE JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 314. FRANCE JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2017-2032 (USD MILLION)
TABLE 315. FRANCE JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2017-2032 (USD MILLION)
TABLE 316. FRANCE JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 317. FRANCE JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 318. FRANCE JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2017-2032 (USD MILLION)
TABLE 319. FRANCE JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 320. CANADA JOINT PAIN INJECTIONS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 321. CANADA JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 322. CANADA JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 323. CANADA JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2017-2032 (USD MILLION)
TABLE 324. CANADA JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 325. CANADA JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2017-2032 (USD MILLION)
TABLE 326. CANADA JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2017-2032 (USD MILLION)
TABLE 327. CANADA JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 328. CANADA JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 329. CANADA JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2017-2032 (USD MILLION)
TABLE 330. CANADA JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 331. ITALY JOINT PAIN INJECTIONS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 332. ITALY JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 333. ITALY JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 334. ITALY JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2017-2032 (USD MILLION)
TABLE 335. ITALY JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 336. ITALY JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2017-2032 (USD MILLION)
TABLE 337. ITALY JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2017-2032 (USD MILLION)
TABLE 338. ITALY JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 339. ITALY JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 340. ITALY JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2017-2032 (USD MILLION)
TABLE 341. ITALY JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 342. AUSTRALIA JOINT PAIN INJECTIONS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 343. AUSTRALIA JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 344. AUSTRALIA JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 345. AUSTRALIA JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2017-2032 (USD MILLION)
TABLE 346. AUSTRALIA JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 347. AUSTRALIA JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2017-2032 (USD MILLION)
TABLE 348. AUSTRALIA JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2017-2032 (USD MILLION)
TABLE 349. AUSTRALIA JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 350. AUSTRALIA JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 351. AUSTRALIA JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2017-2032 (USD MILLION)
TABLE 352. AUSTRALIA JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 353. SOUTH KOREA JOINT PAIN INJECTIONS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 354. SOUTH KOREA JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 355. SOUTH KOREA JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 356. SOUTH KOREA JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2017-2032 (USD MILLION)
TABLE 357. SOUTH KOREA JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 358. SOUTH KOREA JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2017-2032 (USD MILLION)
TABLE 359. SOUTH KOREA JOINT PAIN INJECTIONS MARKET SIZE,

Companies Mentioned

  • Allergan plc
  • Anika Therapeutics, Inc.
  • Anterogen Co., Ltd.
  • Bioiberica S.A.U.
  • Bioventus LLC
  • Boehringer Ingelheim GmbH
  • Chugai Pharmaceutical Co., Ltd.
  • Contipro a.s.
  • Eli Lilly and Company
  • Ferring B.V.
  • Fidia Farmaceutici S.p.A.
  • Hangzhou Singclean Medical Products Co., Ltd.
  • LG Chem Ltd.
  • Mylan N.V.
  • Novartis AG
  • Pacira Pharmaceuticals, Inc
  • Pfizer Inc.
  • Sanofi S.A
  • Seikagaku Corporation
  • Shanghai Jingfeng Pharmaceutical Co., Ltd.
  • Smith & Nephew plc
  • Teva Pharmaceutical Industries Ltd.
  • Yantai Dongcheng Pharmaceutical Group Co., Ltd.
  • Zimmer Biomet Holdings, Inc.

Table Information

Report AttributeDetails
No. of Pages194
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 5.15 Billion
Forecasted Market Value ( USD ) by 2032 $ 9.28 Billion
Compound Annual Growth Rate10.1%
Regions CoveredGlobal
No. of Companies Mentioned24

Related Topics

Related Reports

Steroid Injections Market - Global Forecast 2026-2032 - Product Image

Steroid Injections Market - Global Forecast 2026-2032

  • Report
  • 181 Pages
  • Global
From
Joint Pain Injections - Global Strategic Business Report - Product Image

Joint Pain Injections - Global Strategic Business Report

  • Report
  • 378 Pages
  • Global
From
Viscosupplementation Injection Market - Global Forecast 2026-2032 - Product Image

Viscosupplementation Injection Market - Global Forecast 2026-2032

  • Report
  • 185 Pages
  • Global
From
Joint Pain Injections Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031 - Product Image

Joint Pain Injections Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

  • Report
  • 181 Pages
  • Global
From
Joint Pain Injections Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Joint Pain Injections Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From

About the Joint Pain Injections Market

The Joint Pain Injections market is a subset of the Analgesics market, which is focused on providing relief from pain. Joint Pain Injections are used to treat pain caused by arthritis, bursitis, and other joint-related conditions. These injections are typically administered directly into the affected joint, and can provide relief from pain for several weeks or months. The Joint Pain Injections market is composed of a variety of products, including corticosteroids, hyaluronic acid, and platelet-rich plasma. These products are used to reduce inflammation, lubricate the joint, and promote healing. Some of the companies in the Joint Pain Injections market include Pfizer, Sanofi, and Novartis. Other companies include AbbVie, Merck, and Johnson & Johnson. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.